Cytokines and biotrauma in ventilator-induced lung injury: a critical review of the literature

F.J.J. Halbertsma1,5*, M. Vaneker2*, G.J. Scheffer2, J.G. van der Hoeven3,4

Departments of 1Paediatric Intensive Care, 2Anaesthesiology, 3Intensive Care, 4Nijmegen University Centre for Infectious Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands, 5Department of Neonatal Intensive Care, Maxima Medical Centre, Veldhoven, the Netherlands, *corresponding authors (both contributed equally to the article):
tel.: +31 (0)24-361 72 73, fax: +31 (0)24-354 16 12,
e-mail: F.Halbertsma@mmc.nl, M.Vaneker@anes.umcn.nl

ABSTRACT

Background: Mechanical ventilation is known to induce and aggravate lung injury. One of the underlying mechanisms is biotrauma, an inflammatory response in which cytokines play a crucial role.

Objective: To review the literature on the role of cytokines in ventilator-induced lung injury (VILI) and multiple organ dysfunction syndrome (MODS).

Material and methods: 57 English written, peer-reviewed articles on cytokines in in-vitro settings (n=5), ex-vivo models (n=9) in-vivo models (n=19) and clinical trials (n=24).

Results: Mechanical ventilation (MV) can induce cytokine upregulation in both healthy and injured lungs. The underlying mechanisms include alveolar cellular responses to stretch with subsequent decompartimentalisation due to concomitant cellular barrier damage. The cytokines involved are interleukin (IL)-8 and CXC chemokines, and probably IL-6, IL-1β, and tumour necrosis factor (TNF)-α. Cytokines are important for signalling between inflammatory cells and recruiting leucocytes to the lung. There is strong circumstantial evidence that the release of cytokines into the systemic circulation contributes to the pathogenesis of MODS. Multiple studies demonstrate the relation between elevated proinflammatory cytokine concentrations and mortality.

Conclusion: Cytokines are likely to play a role in the various interrelated processes that lead to VILI and other MV-related complications, such as MODS and possibly ventilator-associated pneumonia. Cytokines are good surrogate endpoints in exploring the pathogenesis and pathophysiology of VILI in both experimental and clinical studies.

KEYWORDS

Cytokines, mechanical ventilation, ventilator-induced lung injury

INTRODUCTION

Mechanical ventilation (MV) is one of the cornerstones of ICU treatment. Despite its lifesaving effects, MV may lead to serious damage in both previously healthy and diseased lungs, a process called ventilator-induced lung injury (VILI; figure 1). In 1974, Webb en Tiernay demonstrated that MV with high peak airway pressures resulted in lung oedema, alveolar disruption, capillary leakage and death.1 Further studies revealed that the end-inspiratory volume and not the end-inspiratory pressure was the main determinant (volutrauma). Subsequent studies showed that cyclic opening and collapse of alveoli, even at low inspiratory pressures and low inspiratory volume, increases stretch and shear forces resulting in lung injury and surfactant dysfunction.2,3 This atelectrauma could be attenuated by increasing positive end-expiratory pressure (PEEP) and outweighed the concomitant increase in inspiratory pressure.1,4 Recent studies have shown that MV upregulates pulmonary cytokine production, which may result in an inflammatory reaction aggravating lung injury (biotrauma). This inflammatory reaction is not confined to the lungs but also involves the systemic circulation and has its effects on distal end-organs, which offers an explanation for the observation that most adult respiratory distress syndrome (ARDS) patients do not die.
from respiratory failure but from multiple organ dysfunction syndrome (MODS). In this review we will discuss the role of cytokines in VILI and relate these findings to the clinical setting.

**Inflammatory response to mechanical ventilation**

Pulmonary injury and inflammation is a complex process in which cytokines play an important role. Cytokines are low-molecular-weight soluble proteins that transmit signals between the cells involved in the inflammatory response. They are produced by bronchial, bronchial and alveolar epithelial cells but also by alveolar macrophages and neutrophils. The balance between the proinflammatory cytokines tumour necrosis factor (TNF)-α, interleukin (IL)-1, IL-6, IL-8 and anti-inflammatory cytokines such as IL-10 is essential for directing the immune response. Some of the cytokines have natural antagonists, for example IL-1ra which makes an interpretation of the net effect cumbersome. TNF-α and IL-1 induce NF-κB activation, a critical step in the transcription of genes necessary to perpetuate the innate immune response that ultimately results in activation and extravasation of polymorphonuclear leucocytes (PMNs) and other immune active cells, a process that starts within minutes after commencing mechanical ventilation. Leucocytes are predominantly activated and attracted to the lungs by CXC chemokines and IL-8. However, alveolar recruitment of PMNs by instilling a chemoattractant (LTB4) does not result in lung injury, indicating that other factors, possibly cytokines, are necessary to activate them. This activation and attraction of leucocytes is a very important feature in biotrauma. Experimental studies using PMN-depleted animals demonstrate a significantly reduced degree of VILI. Also, leucocyte apoptosis appears to be delayed in adult acute lung injury (ALI) and neonatal chronic lung disease (CLD), contrary to pulmonary epithelial cells and other end-organs that exhibit increased apoptosis. Incubation of normal PMNs in bronchoalveolar lavage (BAL) fluid derived from ARDS patients results in delayed apoptosis compared with those incubated in normal BAL fluid. Inhibition of neutrophil apoptosis seems mediated by soluble factors, such as the proinflammatory cytokines, possibly IL-8 and IL-2, granulocyte colony-stimulating factor and granulocyte/macrophage colony-stimulating factor (GM-CSF), and levels of soluble Fas-ligand appear to be higher in BAL fluid derived from ARDS nonsurvivors than in that of survivors. Similarly, Fas, Fas-ligand and Caspase-3 are more prevalent in alveolar walls of patients succumbing to ARDS than in those who died without this diagnosis, and soluble recombinant human Fas ligand infusion in the experimental setting results in increased alveolar apoptosis and injury.

Another important pathophysiological relation in VILI is that between cytokines and surfactant. Surfactant dysfunction or deficiency is one of the prominent features of lung injury. Inflammation and more specifically cytokines such as TNF-α and IL-1 are thought to decrease surfactant components either directly or indirectly by inducing alveolar leakage of proteins that subsequently inhibit surfactant function.

There are several mechanisms by which mediator release may occur during mechanical ventilation: alterations in cytoskeletal structure without ultrastructural damage (mechanotransduction); stress failure of the alveolar barrier (decompartmentalisation), stress failure of the plasma membrane (necrosis), and effects on the vasculature independent of stretch or rupture.

**Mechanotransduction**

One of the most intriguing mechanisms of ventilation-induced cytokine release is mechanotransduction. Transmembrane receptors such as integrins, stretch-activated ion channels and the cytoskeleton itself are identified as the key structures in mechanosensing that start various intracellular processes. Mechanotransduction, the stimulation of gene transcription following mechanosensing, is most likely signalled by mitogen-activated protein kinase (MAPK). Most alveolar cells are capable of producing pro- and anti-inflammatory mediators such as TNF-α, IL-1β, IL-6, IL-8, and IL-10 when stretched in vitro or when ventilated with a large tidal volume (VT) in ex-vivo experiments. In premature neonates, cytokine production appears to be related to gestational age, with a delayed maturation of the anti-inflammatory response. Injurious MV also induces upregulation of genes responsible for c-fos which...
In turn activates transcription for cytokine synthesis, cyclo-oxygenase production and intercellular adhesion molecule (ICAM)-1 expression. NF-κB, a DNA-binding protein, plays a central role as a common messenger in cytokine regulation and inflammation. In experimental models, blockage of NF-κB decreases VILI. However, its exact role in mechanotransduction is not completely clear yet.

Translocation and decompartimentalisation
Besides mechanotransduction, direct trauma to the plasma membrane of alveolar cells and loss of cell integrity leads to the release of intracellular cytokines to the interstitium and decompartimentalisation into both the alveolar space and the systemic circulation. Experiments by Haitsma et al. have demonstrated that in healthy animals ventilated without positive end-expiratory pressure (PEEP), endotracheal instillation of lipopolysaccharide (LPS) to induce local TNF-α production results in elevated serum concentrations of TNF-α, and conversely intraperitoneal LPS injection resulted in TNF-α in BAL fluid.

Cytokines in VILI
Experimental studies
Experimental studies consist of both in-vitro, ex-vivo and in-vivo models, using different species and applying various techniques, which probably explains some of the observed inconsistencies in cytokine response (tables 1 to 3). In almost all studies, cyclic overstretch increases alveolar levels of IL-8 or its rodent equivalent macrophage inflammatory protein (MIP)-2. MIP-2 is the most potent leucocyte chemoattractant and its role in the pathogenesis of VILI is very important. Neutrophil depletion attenuates the increase of IL-8 in the lungs and results in less severe VILI. Activating neutrophils in VILI occurs primarily in the alveolar space after migration. Subsequent lung damage is partly mediated by the interaction of the CXC chemokine receptor 2 ligand in lung tissue with its receptor on neutrophils. Other proinflammatory cytokines such as IL-1β and IL-6 are elevated in most but not all studies. Recombinant IL-1 receptor antagonist attenuates neutrophil recruitment in a lung lavage model. The involvement of another potent proinflammatory cytokine TNF-α in the pathogenesis of VILI is still under debate. Increased TNF-α levels after MV were found in most but not all uninjured lung models, surfactant depletion and ALI models, and sepsis models (tables 2 and 3). Endotracheal instillation of anti-TNF-α antibody attenuates VILI in both the previously uninjured and injured lung, suggesting a role for TNF-α. However, lack of TNF-α signalling (TNF-α receptor -/- mice) does not show diminished VILI. In general, most of the reviewed studies show a more pronounced increase in cytokine levels with larger tidal volumes or absent PEEP or when animals are concomitantly subjected to other injurious strategies such as hyperoxia. The observed proinflammatory response usually parallels the observed histopathology. The injured lung appears to be far more susceptible for VILI than the healthy lung (two-hit model).

Human studies (table 4)
Both short-term and long-term clinical studies have shown that ventilator settings influence pulmonary cytokine levels. Plotz et al. demonstrated that two hours of lung-protective MV (VT 10 ml/kg, 4 cm H2O PEEP, FiO2 0.4) in healthy infants anaesthetised for cardiac catheterisation

Table 1 Experimental in-vitro studies

<table>
<thead>
<tr>
<th>Author, reference</th>
<th>Study subject</th>
<th>Study design</th>
<th>Studied variables</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pugin3</td>
<td>Human alveolar macrophages</td>
<td>A: Static B: Cyclic stretch C: LPS static D: LPS + cyclic stretch</td>
<td>TNF-α, IL-6, IL-8, NF-κB activation</td>
<td>IL-8: A &lt; C &lt; B &lt; D TNF-α, IL-6: A/B = α, C &lt; D Dexamethasone blocks increase of TNF-α, NF-κB A &gt; B</td>
</tr>
<tr>
<td>Vlahakis35</td>
<td>Alveolar epithelium</td>
<td>A: Cyclic stretch B: Static stretch</td>
<td>IL-8</td>
<td>TNF-α: A = B IL-10: A &lt; B</td>
</tr>
<tr>
<td>Blahnik36</td>
<td>Neonatal lung macrophages</td>
<td>LPS stimulation of lung macrophages: A: preterm B: term</td>
<td>TNF-α, IL-10</td>
<td></td>
</tr>
<tr>
<td>Li37</td>
<td>Neonatal lung macrophages</td>
<td>rIL-10/dexamethasone administration</td>
<td>IL-6, TNF-α</td>
<td>Decrease</td>
</tr>
<tr>
<td>Mourgeon38</td>
<td>Foetal rat lung cells</td>
<td>Stretch 0-5% ± LPS</td>
<td>MIP-2</td>
<td>Increase with higher stretch levels especially after LPS</td>
</tr>
<tr>
<td>Grembowicz39</td>
<td>Endothelium</td>
<td>Stretch</td>
<td>c-fos, NF-κB</td>
<td>Increase after plasma membrane disruption</td>
</tr>
</tbody>
</table>
resulted in elevated alveolar IL-6 levels. Stuber et al. showed that increasing Vt from 6 to 12 ml/kg in ARDS patients increases cytokine levels in both BAL fluid and plasma within one hour. These findings are consistent with both the results of Ranieri et al. who found lower cytokine levels in BAL fluid of patients ventilated with low Vt and those of the ARDS network trial in 2000 that found lower plasma IL-6 levels in the low Vt group.

In accordance with experimental data, previously injured lungs may be more susceptible for VILI. Wrigge et al. found elevated cytokine levels after elective surgery in patients with normal lungs, but there was no difference between patients ventilated with Vt 15 ml/kg and those with Vt 6 ml/kg. In longitudinal studies in both adults and neonates, elevated proinflammatory cytokine levels are associated

<table>
<thead>
<tr>
<th>Author, reference</th>
<th>Study subject</th>
<th>Study design</th>
<th>Studied variables</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tremblay</td>
<td>Isolated rat lung, n=55</td>
<td>A: MV Vt 7/PEEP 3</td>
<td>TNF-α, IL-β, IFN-γ, IL-6/10, MIP-2, c-fos mRNA in BAL</td>
<td>A &lt; B &lt; C &lt; D, TNF-α/MIP2/c-fos: LPS &gt; NaCl 0.9%</td>
</tr>
<tr>
<td>Tremblay</td>
<td>Isolated rat lung, n=24</td>
<td>A: MV Vt 7/PEEP 3</td>
<td>TNF-α, IL-6, mRNA, in lung, homogenate, BAL</td>
<td>C and D &gt; A, Time-dependent response, peak at T = 30 min</td>
</tr>
<tr>
<td>Whitehead</td>
<td>Isolated rat lung, n=70</td>
<td>A: MV Vt 7/PEEP 3</td>
<td>TNF-α, IL-β, MIP-2, in BAL</td>
<td>NaCl: TNF-α, IL-β: A &lt; D, LPS: TNF-α, MIP-2 A &gt; D</td>
</tr>
<tr>
<td>Chu</td>
<td>Isolated rat lung, n=88</td>
<td>A: MV Vt 7 PEEP 5</td>
<td>TNF-α, IL-6, mRNA, in lung, homogenate, BAL</td>
<td>NaCl: TNF-α, IL-β, MIP-2, in serum and BAL</td>
</tr>
<tr>
<td>Bethmann</td>
<td>Isolated mouse lung, n=27</td>
<td>A: MV ΔP 10</td>
<td>TNF-α, IL-6, mRNA</td>
<td>A &lt; B in both positive and negative pressure ventilation</td>
</tr>
<tr>
<td>Cheng</td>
<td>Isolated mouse lung, n=nd</td>
<td>A: MV Vt 7 ZEEP 0</td>
<td>TNF-α, MIP-1, lung dynamics</td>
<td>C &gt; A/B, C &lt; B/A</td>
</tr>
<tr>
<td>Bailey</td>
<td>Isolated mouse lung, n=106</td>
<td>A: FiO2 0.21</td>
<td>TNF-α, IL-6 in BAL</td>
<td>TNF-α: B + MV &gt; B − MV, IL-6: B &gt; A ± MV</td>
</tr>
<tr>
<td>Held</td>
<td>Isolated mouse lung, n=31</td>
<td>A: MV Vt 9 ΔP 10</td>
<td>MIP-2, MIP-1a, NFκB in BAL and Serum</td>
<td>BAL/serum: B = C &gt; A, Attenuation by dexamethasone</td>
</tr>
<tr>
<td>Author, reference</td>
<td>Study subject</td>
<td>Study design</td>
<td>Studied variables</td>
<td>Results</td>
</tr>
<tr>
<td>-------------------</td>
<td>---------------</td>
<td>--------------</td>
<td>-------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Wilson90</td>
<td>Mouse, n=29</td>
<td>A: MV Vt 9</td>
<td>TNF-α, MIP-2 in BAL</td>
<td>A &lt; B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B: MV Vt 35</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wilson46</td>
<td>Mouse, n=15</td>
<td>A: MV Vt 10</td>
<td>MIP-2 in BAL</td>
<td>A &lt; B in all mice</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B: MV Vt 44</td>
<td>Pulmonary PMN influx</td>
<td>PMN influx less in knock-out and anti-TNF e.t. mice,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lung injury</td>
<td>not in anti-TNF i.v. mice</td>
</tr>
<tr>
<td>Belperio44</td>
<td>Mouse, n=30</td>
<td>A: MV PIP 20</td>
<td>KC/CXCL1,</td>
<td>A &lt; B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B: MV PIP 40</td>
<td>MIP-2/CXCL2/3 in lung tissue</td>
<td>Less in CXCR2 / mice</td>
</tr>
<tr>
<td>Gurkan93</td>
<td>Rat, n=26</td>
<td>A: MV Vt 6</td>
<td>IL-6, TNF-α, VEGF in BAL</td>
<td>NaCl: A = B = 0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B: MV Vt 17</td>
<td></td>
<td>FiCl: IL-6, VEGF: A &lt; B</td>
</tr>
<tr>
<td>Chiumello44</td>
<td>Rat, n=40</td>
<td>A: MV Vt 16 PEEP 0</td>
<td>TNF-α, MIP-2 in serum and BAL</td>
<td>BAL: TNF-α: A &gt; D &gt; B &gt; E</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B: MV Vt 16 PEEP 5</td>
<td></td>
<td>Serum TNF: A &gt; B = D = E</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C: MV Vt 9 PEEP 0</td>
<td></td>
<td>BAL: MIP-α: A &gt; B = D = E</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D: MV Vt 9 PEEP 5</td>
<td></td>
<td>Serum MIP: A &gt; B &gt; D = E</td>
</tr>
<tr>
<td></td>
<td></td>
<td>E: MV Vt 9 PEEP 5 + RM HCl e.t.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caruso96</td>
<td>Rat, n=30</td>
<td>A: spontaneous ventilation</td>
<td>IL-1β mRNA in lung tissue</td>
<td>A &lt; B = C</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B: MV Vt 6</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>C: MV Vt 24</td>
<td>L infiltration</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vt 25 PEEP 0</td>
<td>HSP-70, IL-1β in lung tissue</td>
<td>Increase after 90 min MV</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vt 16 PEEP 5</td>
<td>mRNA IL-1β, IL-6, IL-10 TNF-α, MIP-2 in lung tissue</td>
<td>A/B: all parameters: adult &gt; neonatal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vt 9 PEEP 0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vt 9 PEEP 5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imanaka25</td>
<td>Rat, n=23</td>
<td>A: MV PIP 45 PEEP 0</td>
<td>TNF-α mRNA, TGFβ1 mRNA PMN ICAM</td>
<td>No increase</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B: MV PIP 7 PEEP 0</td>
<td></td>
<td>A = B</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>A &lt; B</td>
</tr>
<tr>
<td>Verbrugge95</td>
<td>Rat, n&gt;100</td>
<td>Lung lavage model</td>
<td>TNF-α, protein in BAL</td>
<td>B &lt; A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A: MV + Surfactant</td>
<td></td>
<td>TNF-α: A = B = C = D = E</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B: Partial liquid vent</td>
<td></td>
<td>Protein: A = B = C &lt; D = E</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C: MV PEEP 16</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>D: MV PEEP 8</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>E: MV PIP 32/6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quinn97</td>
<td>Rat, n=35</td>
<td>A: MV FiO 2 0.21</td>
<td>MIP-2, WBC in BAL</td>
<td>B &gt; A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B: MV FiO 2 1.0</td>
<td>Lung weight</td>
<td>B &gt; A</td>
</tr>
<tr>
<td>Bueno96</td>
<td>Rat, n=33</td>
<td>A: Vt 7</td>
<td>TNF-α in plasma</td>
<td>C &gt; A/B (ns) PaO2: C &lt; A/B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B: Vt 21</td>
<td></td>
<td>Lung weight: A/B &lt; C</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C: Vt 42</td>
<td>PaO2, lung weight</td>
<td>A/B/C: increase MIP-2 in BAL</td>
</tr>
<tr>
<td>Haitsma99</td>
<td>Rat, n=85</td>
<td>A: MV P 13/3</td>
<td>IL-6, MIP-2 in BAL and serum</td>
<td>B/C: increase MIP-2 in serum</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B: MV P 32/6</td>
<td></td>
<td>C: increase IL-6 in serum,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C: MV P 32/0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haitsma41</td>
<td>Rat, n=85</td>
<td>A: MV P 45/0</td>
<td>TNF-α in serum and BAL</td>
<td>A &gt; B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B: MV P 45/10</td>
<td></td>
<td>LPS &gt; NaCl</td>
</tr>
<tr>
<td>Lin76</td>
<td>Rat, n=50</td>
<td>A: MV Vt 7 PEEP 5 lh/day</td>
<td>MIP-2, TNF-α in serum and BAL</td>
<td>A &gt; B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B: MV Vt 21 PEEP 0 lh/day</td>
<td>Blood cultures</td>
<td>A &lt; B positive</td>
</tr>
</tbody>
</table>
### Table 3

<table>
<thead>
<tr>
<th>Author, reference</th>
<th>Study subject</th>
<th>Study design</th>
<th>Studied variables</th>
<th>Results</th>
</tr>
</thead>
</table>
| Herera\(^{105}\)  | Rat, n=125    | A: MV Vt 6  
B: MV Vt 20  
PEEP vs ZEEP | IL-1β, IL-6, TNF-α serum, mRNA in lung tissue | B ZEEP > A ZEEP > A PEEP |
| Takata\(^{106}\)  | Rabbits, n=13 | MV P 28/5    | TNF-α mRNA in lung lavage cells | Increase |
| Imai\(^{47}\)     | Rabbits, n=25 | A: MV Anti-TNF-α e.t.  
B: MV IgG e.t.  
C: MV NaCl e.t. | WBC in BAL | A < B = C |
| Narimanbekov\(^{51}\) | Rabbits | A: FIO\(_2\) 0.21 low PIP  
B: FIO\(_2\) 1.0 high PIP  
C: B + rIL-1 antagonist | WBC in BAL | A, C < B |

### Table 4 Human studies

<table>
<thead>
<tr>
<th>Author, reference</th>
<th>Study subject</th>
<th>Study design</th>
<th>Studied variables</th>
<th>Results</th>
</tr>
</thead>
</table>
| Ranieri\(^{52}\)  | ARDS, n=44    | A: Vt 11 PEEP 6.5  
B: Vt 7.5 PEEP 14.8 | Most variables A > B |         |
| Stuber\(^{55}\)   | ALL, n=12     | A: Vt 5 PEEP 15 (6H)  
A2: Vt 12 PEEP 5 (6H)  
A3: Vt 5 PEEP 15 (6H) | Serum A1 = A3 < A2  
BAL A1 < A2 < A3 |         |
| Wrigge\(^{33}\)   | Elective surgery, n=39 | A: Vt 15 PEEP o  
B: Vt 6 PEEP o  
C: Vt 6 PEEP 10 | A = B = C |         |
| Wrigge\(^{34}\)   | Thoracotomy/ laparotomy, n=34/30 | A: Vt 12-15 PEEP o  
B: Vt 6 PEEP 10 | A = B = C |         |
| ARDS network\(^{56}\) | ARDS, n=861  | A: Vt 6  
B: Vt 12 | IL-6  
Mortality | A < B  
A < B |
| Meduri\(^{60}\)   | ARDS, n=27    | A: survivors  
B: nonsurvivors | TNF-α, IL-1β, IL-6, IL-8 | A < B  
A < B |
| Meduri\(^{61}\)   | Persistent ARDS, n=17 | A: R/methylprednisolone  
B: R/- | TNF-α, IL-1β, IL-6  
IL-10 mRNA in cells primed with plasma | A < B  
A > B |
| Headley\(^{73}\)  | ARDS, n=43    | A: survivors  
B: nonsurvivors | TNF-α, IL-1β, IL-6, IL-8 | A < B |
| Douzinas\(^{65}\) | Sepsis/ARDS, n=8 | Mechanical ventilation | TNF-α, IL-6,  
Anti-inflammatory cytokines/ pro-inflammatory cytokines | Arterial > venous  
A > B, both > I |
| Park\(^{9}\)      | ARDS, n=69    | A: patients at risk for ARDS  
B: patients developing ARDS | TNF-α, TNF-α R I & II, IL-1β, IL-RA, sol IL-1β r II, IL-6, sol IL-6 r, IL-8 | IL-6, IL-8: A < B  
Mortality and morbidity related with IL-6, IL-8 |
| Parsons\(^{70}\)  | ALL, n=861    | A: Vt 6  
B: Vt 12 | IL-6, IL-8, IL-10 | A > B  
Mortality related with IL-6, IL-8 |
| Parsons\(^{70}\)  | ALL, n=95     | A: Vt 6  
B: Vt 12 | Sol TNF receptor I | A < B |
| Plotz\(^{49}\)    | Infants, n=12 | Vt 10 PEEP 4 | TNF-α, IL-6 | Increased after 2 hours |
| Yoon\(^{93}\)     | Neonates, n=69 | Intrauterine infection | IL-6, CLD | IL-6 related to CLD  
Detectable |
| Wang\(^{74}\)     | Neonates, n=34 | Mechanical ventilation | IL-16 in BAL | Associated with increased BAL L |
with more severe lung injury and worse outcome, supporting the concept that lung injury is partly the result of a massive proinflammatory response.\textsuperscript{60,62}

**Cytokines and multiple organ dysfunction syndrome**

In patients with ARDS the highest cytokine concentrations are found downstream from the lung.\textsuperscript{55} Thus biotrauma is not only confined to the lungs but may also result in a systemic inflammatory response syndrome (SIRS)\textsuperscript{52,61,62,64} and distant organ apoptosis,\textsuperscript{20} both leading to MODS and death. This offers an explanation for the observation that most patients with ARDS do not die from respiratory failure but from MODS.\textsuperscript{3} The presumed causal relation between a ventilation-induced increase in systemic cytokine levels and subsequent MODS is an interesting hypothesis.\textsuperscript{52,61,62,65-69} Several studies have found plasma cytokine levels to be higher during large tidal volume ventilation.\textsuperscript{51,52,70,71} and associated with the development of MODS,\textsuperscript{72} and persistent cytokine elevation in turn is associated with a poor outcome in patients with ARDS.\textsuperscript{60,73}

Another important mechanism contributing to the development of MODS is the ventilation-induced enhancement of local dissemination of bacteria\textsuperscript{74} and compartmentalisation of bacteria and endotoxins from the alveolar space into the circulation.\textsuperscript{75-77} Bacteria derived from BAL fluid from ARDS patients with persistent local inflammation exhibit enhanced growth capacity when incubated with proinflammatory cytokines.\textsuperscript{78} Kanangat et al. showed that the induction of cytokines by LPS diminished the bacterial killing capacity of monocytes.\textsuperscript{79} This supports the theory that a persistent local proinflammatory reaction may be a risk factor for developing a ventilator-associated pneumonia (VAP).\textsuperscript{80} In-vitro corticosteroids block these increased bacterial growth capacities in the presence of high proinflammatory cytokine concentrations.\textsuperscript{81} If confirmed this may be an interesting new strategy in preventing VAP in certain selected patient groups.

The role of immunomodulation on the clinical course of VILI and MODS needs further investigation. In neonatal RDS, early treatment with corticosteroids has significantly decreased the inflammatory response,\textsuperscript{82} diminished CLD and dramatically improved survival, the contribution of corticosteroids in (late) adult ARDS is still controversial.\textsuperscript{83}

**Conclusions**

There is a growing body of evidence that mechanical ventilation may sensitise the innate immune system and that in turn the innate immune system may sensitise the lungs to the effects of mechanical ventilation. This explains the exaggerated ventilation-induced inflammatory response in preinjured lungs and is of great clinical importance.\textsuperscript{84} Cytokines play an important role in the various interrelated processes that lead to ventilator-induced lung injury and other related systemic complications, such as multiple organ dysfunction syndrome and possibly ventilator associated pneumonia.

---

<table>
<thead>
<tr>
<th>Author, reference</th>
<th>Study subject</th>
<th>Study design</th>
<th>Studied variables</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kwong\textsuperscript{55}</td>
<td>Premature neonates, n=15</td>
<td>Mechanical ventilation</td>
<td>IL-1β, IL-8, IL-10 in BAL</td>
<td>IL-10 undetectable</td>
</tr>
<tr>
<td>Mc Colm\textsuperscript{56}</td>
<td>Preterm neonates, n=17</td>
<td>Mechanical ventilation</td>
<td>IL-1β, IL-8, IL-10 in BAL</td>
<td>IL-10 detectable in CLD, elevated IL-1β, IL-8</td>
</tr>
<tr>
<td>Oei\textsuperscript{59}</td>
<td>Neonates, n=48</td>
<td>Mechanical ventilation</td>
<td>IL-10 in BAL</td>
<td>IL-10 increases with GA</td>
</tr>
<tr>
<td>Schultz\textsuperscript{57}</td>
<td>Neonates, n=20</td>
<td>RDS</td>
<td>IL-10 in BAL</td>
<td>Low IL-10 in CLD</td>
</tr>
<tr>
<td>Gromeck\textsuperscript{51}</td>
<td>Neonates, n=59</td>
<td>Follow-up infants with prolonged MV need</td>
<td>IL-8 in BAL</td>
<td>Elevated pro-inflammatory cytokines, stable IL-10</td>
</tr>
<tr>
<td>Hitti\textsuperscript{56}</td>
<td>Neonates, n=136</td>
<td>A: RDS B: no RDS</td>
<td>TNF-α in BAL</td>
<td>A &gt; B</td>
</tr>
<tr>
<td>Jonsson\textsuperscript{57}</td>
<td>Neonates, n=28</td>
<td>A: CLD B: no CLD</td>
<td>IL-1β, IL-6, IL-8 in BAL</td>
<td>A &gt; B</td>
</tr>
<tr>
<td>Munshi\textsuperscript{58}</td>
<td>Neonates, n=56</td>
<td>A: RDS progress to BPD B: RDS resolving</td>
<td>IL-6, IL-8 in BAL</td>
<td>A &gt; B</td>
</tr>
</tbody>
</table>
ABBREVIATIONS

ΔP = PIP-PEEP difference  
ALI = acute lung injury  
ARDS = adult respiratory distress syndrome  
BAL = bronchoalveolar lavage  
BPD = bronchopulmonary dysplasia  
CLD = chronic lung disease  
CPAP = continuous positive airway pressure  
e.t. = endotracheal  
FiO₂ = fractional inspired oxygen  
HSP = heat shock protein  
ICAM = intercellular adhesion molecule  
IL = interleukin  
i.v. = intravenous  
LPS = lipopolysaccharide  
MIP = macrophage inflammatory protein  
MV = mechanical ventilation  
n.d = not documented  
NEEP = negative end-expiratory pressure (in cm H₂O)  
PaO₂ = pulmonary artery oxygen  
PEEP = positive end-expiratory pressure (in cm H₂O)  
PIP = peak inspiratory pressure (in cm H₂O)  
PMN = polymorphonuclear leucocytes  
RA = receptor antagonist  
RDS = respiratory distress syndrome  
rIL = recombinant interleukin  
RM = recruitment maneuver  
SOL = soluble  
TNF = tumour necrosis factor  
VEGF = vascular endothelial growth factor  
Vt = tidal volume (in ml/kg)  
WBC = white blood cells  
ZEEP = zero end-expiratory pressure

REFERENCES


42. Bailey TC, Martin EL, Zhao L, Veldhuizen RA. High oxygen concentrations predispose mouse lungs to the deleterious effects of high stretch ventilation. J Appl Physiol 2003;94(3):975-82.


